Navigation Links
QRxPharma Doses First Patients in Phase III Clinical Trial Program for its 'Dual Opioid' Pain Therapy
Date:11/26/2007

First study to focus on acute, post-surgical pain, with a follow-on safety extension trial to begin in late-2007

SYDNEY, Australia, Nov. 26 /PRNewswire-FirstCall/ -- QRxPharma (ASX: QRX) announced today that a number of patients have been treated in the first of several clinical studies to be conducted as part of the Phase III development program for its lead product candidate Q8003IR, an immediate release dual-opioid pain therapy.

The initial clinical trial is a double-blind, placebo-controlled study designed to compare the efficacy and safety of four different dosage strengths of Q8003IR vs. placebo in a post-surgery, acute pain setting. The study is being conducted at 8 US clinical research sites and is targeted to enroll 250 patients experiencing moderate to severe pain following a scheduled surgical procedure (bunionectomy).

"Initiation of this Phase III clinical trial program not only demonstrates the Company's ability to deliver on its development milestones for Q8003IR in terms of budget and time-line projections, but also represents a significant step forward towards our goal of commercializing our first dual-opioid pain therapy in 2010," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma.

The primary clinical endpoints for this acute, post-surgery pain study focus on pain relief and pain intensity scores vs. placebo over the first 48 hours post-surgery. Secondary endpoints include: (1) efficacy relating to the time to onset of analgesia and the duration of effect from a single oral dose; and (2) safety as measured by the incidence and intensity of opioid-related adverse events. A safety extension trial will immediately follow patient enrollment in this first trial to begin capturing longer-term patient safety data in support of our planned future New Drug Application (NDA) data submission package for Q8003IR.

Q8003IR is a patent-protected, immediate release dual-opioid product
'/>"/>

SOURCE QRxPharma
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
2. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
3. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
6. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
7. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
8. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
9. Tainted Chinese Food Ingredients First Discovered in 2005
10. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
11. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... Israel , July 21, 2014 ... "Integrity"), developer of the GlucoTrack ® model ... that it has entered, through its wholly-owned subsidiary, ... Wistron Corp, the manufacturing arm of Acer Inc.  ... manufacture and service (on a non-exclusive basis) the ...
(Date:7/21/2014)... JOLLA, Calif. , July 21, 2014 /PRNewswire/ ... ), a biopharmaceutical company leading the discovery and ... that the U.S. Food & Drug Administration (FDA) ... single stranded, chemically modified oligonucleotide that binds to ... a therapeutic for the treatment of Alport syndrome, ...
(Date:7/21/2014)... DIEGO , July 21, 2014  An International ... a redesign of its iCH CPAP device, Taiwanese device ... humidification. ResMed (NYSE: RMD ) is the ... for the treatment of sleep-disordered breathing. ... improving designs to reach new levels of comfort, performance ...
Breaking Medicine Technology:Integrity Applications, Inc. Enters into Manufacturing Agreement with Wistron Corp. 2Integrity Applications, Inc. Enters into Manufacturing Agreement with Wistron Corp. 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 2Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 5ITC Rules Redesigned APEX Humidifier Still Infringes ResMed Patents 2
... OSLO, Norway, October 31, 2011 Oslo ... oncology. The true strength of the Norwegian cluster lies ... than the ones available to cancer patients today. ... cluster within the field of oncology, dedicated to accelerating ...
... Inc. (ARKRAY) announced today that the GLUCOCARD® Vital and ... (DoD) Uniform Formulary.  The DoD Pharmacy and Therapeutic committee ... 01 Blood Glucose Meters as the first and second ... of service as noted by the Uniform Formulary Beneficiary ...
Cached Medicine Technology:Expanding Norwegian Cluster of Excellence Dedicated to Oncology 2Expanding Norwegian Cluster of Excellence Dedicated to Oncology 3ARKRAY's GLUCOCARD® Vital and 01 Blood Glucose Meters are now on the Department of Defense Uniform Formulary. 2
(Date:7/22/2014)... 2014 Bramal LED announced that they will ... Begley Jr, airing later this year via Discovery Channel. Dates ... learn about Bramal LED’s T-10 lamps, which provide over 80,000 ... up to 70 percent. Bramal LED’s T-10 lamps can be ... seconds or on direct AC voltage, with no need for ...
(Date:7/22/2014)... 2014 Chris Carpenter’s Info Cash ... takes a comprehensive, step-by-step approach to teaching the techniques ... has just been released to the public, prompting a ... marketing world if you’re unable to generate traffic you’re ... people simply give up when they find traffic generation ...
(Date:7/22/2014)... NY (PRWEB) July 22, 2014 BlackBox ... Blast Gauge™ System with advancements including a ... The new gauges represent a functional revision of the ... capability to capture complex data on blast events by ... resulting accelerations. The extreme changes in overpressure that accompany ...
(Date:7/22/2014)... BESLER Consulting, a leading provider of ... is pleased to offer a complimentary version of ... hospitals with analyzing their 2015 QualityNet Hospital-Specific Reports ... 21 allow hospitals to validate their Medicare readmissions ... data contained in these reports can be cumbersome ...
(Date:7/22/2014)... One woman who looked at diet pills ... pounds. Unfortunately, the weight loss came at a price – ... her time using the pill, and says her personality changed ... insomnia as a result of the caffeine content of one ... age of 37 because of a diet pill she was ...
Breaking Medicine News(10 mins):Health News:Bramal LED to be featured in Upcoming Episode of Innovations with Ed Begley, Jr. 2Health News:Info Cash 2.0: Review Of Chris Carpenter’s Online Marketing Training Released 2Health News:BlackBox Biometrics®, Inc. continues to advance blast overpressure measurement with release of new Blast Gauge 2Health News:BlackBox Biometrics®, Inc. continues to advance blast overpressure measurement with release of new Blast Gauge 3Health News:Complimentary Re-admissions Analytics Tool Available From BESLER Consulting 2Health News:SlimPlate System Urge Women to Shun Controversial Weight Loss Pills for Healthier Methods Like Portion Control 2
... Mercedes Walton, CEO of Cryo-Cell International, one of the ... progress to date and encouraging continued momentum for existing bills through ... Cord Blood Banking Act," and H.R. 2107, the "Cord Blood Education ... progress from the first half of the year to enable and ...
... Sociological Association,s 104th annual meeting, will be the subject ... present research and explore the politics, history, health and ... More than 5,000 sociologists will convene in the ... New Politics of Community," the meeting,s theme. In addition ...
... , SAN DIEGO, July 6 ADVENTRX Pharmaceuticals, Inc. ... it has completed the previously announced sale of shares ... to a registered direct offering to a single institutional ... percent, or approximately $340,250, of the gross proceeds will ...
... showed muscle fiber damage even after halting drugs, researchers say ... used to lower cholesterol, may cause structural damage to the ... study has found. , The damage may occur even when ... and may persist even after statin use is halted, according ...
... Eli Lilly and Company (NYSE: LLY ) will ... Wednesday, July 22, 2009. Lilly will also conduct a conference ... further detail the company,s financial performance. , , The ... EDT. Investors, media and the general public can access a ...
... Inc. (Nasdaq: SLTM ), a global leader in ... an amendment with Silicon Valley Bank, a member company of ... the company,s credit facility has been expanded from $9 million ... the secured revolving loan facility to $8.0 million, an amendment ...
Cached Medicine News:Health News:Stem Cell Industry Expert Praises, Encourages Continued Progress on Legislation to Promote Benefits of Cord Blood 2Health News:Stem Cell Industry Expert Praises, Encourages Continued Progress on Legislation to Promote Benefits of Cord Blood 3Health News:Sociologists to turn the sociological eye on San Francisco 2Health News:ADVENTRX Pharmaceuticals Announces Closing of Financing 2Health News:ADVENTRX Pharmaceuticals Announces Closing of Financing 3Health News:ADVENTRX Pharmaceuticals Announces Closing of Financing 4Health News:Statins May Cause Muscle Damage in Some Patients 2Health News:Statins May Cause Muscle Damage in Some Patients 3Health News:Solta Medical, Inc. Signs Amendment to Expand Its Credit Facility With Silicon Valley Bank 2Health News:Solta Medical, Inc. Signs Amendment to Expand Its Credit Facility With Silicon Valley Bank 3
... Shepard Clear Corneal Diamond Knife is a ... Dennis Shepard of Santa Maria, California. This ... Shepard's need for a quality instrument that ... Corneal Surgical technique. Through professional collaboration between ...
The new TRC-NW200 Non-Mydriatic Retinal Camera combines Topcons years of experience in retinal imaging with the latest advances in digital and electronic technology....
... Software is a new approach to practice management, ... face in todays healthcare market. OPIE was created ... who work exclusively in this field, so it ... functional and easy-to-use than anything else available. If ...
... The DioLite 532 laser is ... and pigmented skin lesions such as ... port wine stains, lentigines, dermatosis papulosis ... technology offers unsurpassed reliability, a selection ...
Medicine Products: